<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537287</url>
  </required_header>
  <id_info>
    <org_study_id>PDPTL</org_study_id>
    <nct_id>NCT03537287</nct_id>
  </id_info>
  <brief_title>Different Types of Progesterone in the Prevention of Preterm Labor</brief_title>
  <official_title>Intramuscular 17Alpha-hydroxyprogestrone, Progesterone Suppositories and Dydrogesterone Tablets in Preventing Preterm Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm birth is a common problem in obstetric care,with estimates ranging from 5% in several&#xD;
      European countries to 18% in some African countries, Preterm labor defined as delivery before&#xD;
      37 completed weeks is the leading cause of perinatal and neonatal morbidity and mortality and&#xD;
      strongly related to the developmental and neurological disabilities later in life..&#xD;
&#xD;
      There is still considerable uncertainty regarding the optimal progesterone type, route of&#xD;
      administration, dosage and timing of start of therapy to prevent preterm labor in risky women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to compare between the efficacy of intramuscular 17alpha-hydroxyprogestrone,&#xD;
      progesterone vaginal suppositories and dydrogesterone oral tablets in prevention of preterm&#xD;
      labor in high risk women.&#xD;
&#xD;
      All women will be counseled regarding mode of intervention and informed consent will be&#xD;
      obtained. All cases will be subjected to complete history taking, routine antenatal&#xD;
      examination and investigations, treatment of genital or urinary tract infections if&#xD;
      diagnosed. Routine obstetric ultrasound examination and measurement of cervical length by&#xD;
      transvaginal ultrasound will be carried out at 16-18weeks of pregnancy.&#xD;
&#xD;
      The study population will be randomly distributed according to the mode of intervention into&#xD;
      3 groups.&#xD;
&#xD;
      Randomization is performed using a Computer-generated randomization system. Blinding of the&#xD;
      intervention is not feasible in this trial (owing to the different route of administration of&#xD;
      the studied drugs).Table of randomization is obtained&#xD;
&#xD;
      Group 1:&#xD;
&#xD;
      Women who will take intramuscular 17 alpha hydroxyprogestrone caproate&#xD;
&#xD;
      Dose:&#xD;
&#xD;
      250 mg intramuscularly, once weekly starting from 16 weeks till delivery or 36 weeks.&#xD;
&#xD;
      Group 2 :&#xD;
&#xD;
      Women who will take progesterone 200mg vaginal suppositories.&#xD;
&#xD;
      Dose:&#xD;
&#xD;
      Once per day starting from 16 weeks till delivery or 36 weeks&#xD;
&#xD;
      Group 3 :&#xD;
&#xD;
      Women who will take oral dydrogesterone&#xD;
&#xD;
      Dose:&#xD;
&#xD;
      Take 2 tablets a day starting from 16 weeks till delivery or 36 weeks&#xD;
&#xD;
      Color Doppler blood flow velocity examination of fetal circulation will be performed by an&#xD;
      independent investigator blinded to treatment before treatment &amp;after two weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational age in weeks at delivery.</measure>
    <time_frame>6 months</time_frame>
    <description>using either the last menstrual period in patients with regular cycles or early first trimester ultrasound to calculate the gestational age in weeks at delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes in fetoplacental circulation</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of U/S Doppler indices of umbilical artery and middle cerebral artery (namely PI, RI and S/D ratio) in fetal circulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsatisfactory response</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients who needed to increase the dose above the recommended initial dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure of prevention of preterm labor</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients who suffered preterm labor and needed tocolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>6 months</time_frame>
    <description>Birth weight in Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal APGAR score</measure>
    <time_frame>6 months</time_frame>
    <description>Neonatal Apgar score at 1 and 5 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for NICU admission</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients whose neonates were admitted to NICU&#xD;
Neonatal mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Number of neonatal deaths</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>17 alpha hydroxyprogestrone caproate Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal progesterone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral dydrogesterone Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 alpha hydroxyprogestrone caproate</intervention_name>
    <description>250 mg of 17 alpha hydroxyprogestrone caproate weekly</description>
    <arm_group_label>17 alpha hydroxyprogestrone caproate Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal progesterone</intervention_name>
    <description>200 mg of vaginal progesterone daily</description>
    <arm_group_label>Vaginal progesterone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral dydrogesterone</intervention_name>
    <description>2 tablets of dydrogesterone daily</description>
    <arm_group_label>Oral dydrogesterone Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Living fetus with gestational age 16-18weeks (calculated according to date of last&#xD;
             menstrual period confirmed with earlier ultrasound examination).&#xD;
&#xD;
          -  Presence of risk factor for preterm labor:&#xD;
&#xD;
               1. Previous spontaneous preterm labor in previous singleton Pregnancy, OR&#xD;
&#xD;
               2. Previous spontaneous second trimestric miscarriage less than 3 times, OR&#xD;
&#xD;
               3. Short cervix less than 25mm diagnosed during midtrimesteric transvaginal&#xD;
                  ultrasound examination at 16-18 weeks with or without history of previous preterm&#xD;
                  labor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancy.&#xD;
&#xD;
          -  Medical or obstetric conditions requiring termination of pregnancy&#xD;
&#xD;
          -  Contraindication to progesterone administration or its use earlier in this pregnancy&#xD;
&#xD;
               -  Current or past history of thrombophlebitis, thromboembolic disorders, or&#xD;
                  cerebral apoplexy.&#xD;
&#xD;
               -  Liver dysfunction or disease.&#xD;
&#xD;
               -  Known or suspected malignancy of breast or genital organs.&#xD;
&#xD;
               -  Undiagnosed vaginal bleeding.&#xD;
&#xD;
               -  Missed abortion.&#xD;
&#xD;
               -  Known sensitivity to progesterone injection.&#xD;
&#xD;
               -  Known sensitivity to sesame oil/seeds.&#xD;
&#xD;
          -  Congenital fetal anomalies&#xD;
&#xD;
          -  Cervical cerclage in the current pregnancy.&#xD;
&#xD;
          -  Presence of uterine anomalies (Unicornuate uterus , Uterus didelphys, bicornuate&#xD;
             uterus,Septated uterus) or uterine fibroid.&#xD;
&#xD;
          -  Presence of history of chronic hypertetion, chronic liver or kidney diseases, and&#xD;
             pregnancy induced hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Samy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M Samy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Samy, MD</last_name>
    <phone>01001947488</phone>
    <email>mohammedsamy8132@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain SHams Maternity Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbaseya</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Samy, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>mohammed mahmoud samy</investigator_full_name>
    <investigator_title>Lecturer in Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

